Across TCGA pan-cancer cohorts, PNRC2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PNRC2 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PNRC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PNRC2 expression acts as an unfavorable survival marker.
STAD, HNSC, and UCEC are the cancer types where PNRC2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.